ArticleNeuro-oncology2009
Pediatric glioblastomas: a histopathological and molecular genetic study.
Article in Neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 106 citations in OpenAlex.
- Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.Cancer chemotherapy and pharmacology · 2019Trial
- TRK Inhibitors in Adult and Pediatric High-Grade Gliomas: A Systematic Review and Individual Participant Data Meta-Analysis.Cancers · 2025Review
- Discovery of miRNA-mRNA regulatory networks in glioblastoma reveals novel insights into tumor microenvironment remodeling.Scientific reports · 2024Article
- Article
- Pediatric extra-axial glioblastoma with bone invasion leading to a subcutaneous mass: A case report.Surgical neurology international · 2024Article
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Review
- Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series.Genes · 2022Article
- Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations.Frontiers in immunology · 2022Review
- PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.Brain sciences · 2021Article
- Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas.Frontiers in neurology · 2021Review
- A comparative study of brain tumor cells from different age and anatomical locations using 3D biomimetic hydrogels.Acta biomaterialia · 2020Article
- Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.Pediatric research · 2020Article
- H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019Article
- The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.Frontiers in bioengineering and biotechnology · 2019Review
- FNA Cytology in pediatric small cell glioblastoma.Acta bio-medica : Atenei Parmensis · 2018Article
- A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.Pediatric blood & cancer · 2017Article
- Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Article
- Unilateral malignant optic glioma following glioblastoma multiforme in the young: a case report and literature review.BMC ophthalmology · 2017Article
- Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children.Neuro-oncology practice · 2016Article
Corrections and comments
- Commented on by
- Erratum issuedPathak, Pankaj [added]
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) occurs rarely in children. Relatively few studies have been performed on molecular properties of pediatric GBMs. Our objective in this study was to evaluate the genetic alterations in pediatric GBM (age < or = 18 years) with special reference to p53, p16, and p27 protein expression, alterations of the epidermal growth factor receptor (EGFR), and deletion of the phosphate and tensin homolog gene (PTEN). Thirty cases of childhood GBMs reported between January 2002 and June 2007 were selected, and slides stained with hematoxylin and eosin were reviewed. Immunohistochemical staining was performed for EGFR, p53, p16, and p27, and tumor proliferation was assessed by calculating the MIB-1 labeling index (LI). Fluorescence in situ hybridization analysis was performed to evaluate for EGFR amplification and PTEN deletion. Histopathological features and MIB-1 LI were similar to adult GBMs. p53 protein expression was observed in 63%. Although EGFR protein overexpression was noted in 23% of cases, corresponding amplification of the EGFR gene was rare (5.5%). Deletion of the PTEN gene was also equally rare (5.5%). One case showed polysomy (chromosomal gains) of chromosomes 7 and 10. Loss of p16 and p27 immunoexpression was observed in 68% and 54% of cases, respectively. In pediatric de novo/primary GBMs, deletion of PTEN and EGFR amplification are rare, while p53 alterations are more frequent compared to primary adult GBMs. Frequency of loss of p16 and p27 immunoexpression is similar to their adult counterparts. This suggests that pediatric malignant gliomas are distinctly different from adult GBMs, highlighting the need for identification of molecular targets that may be adopted for future novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.